CORRESPONDENCE

Patient-Centred Care through Storytelling
In February 2017, the Canadian Society of Hospital Pharmacists (CSHP) launched the Excellence in Hospital Pharmacy program, a strategic initiative designed to improve patient health outcomes. 1 Of the 3 priority themes of this program, I believe the most vital is patient engagement/patient-centred care. As technology advances, it seems that we are becoming less patient-centred. We now make most treatment decisions with a computer, not the patient. We depersonalize patients by reducing them to a list of diagnoses or a room number. When patients are admitted to hospital, we essentially infringe upon their basic human rights by removing their independence, privacy, dignity, and control, not to mention their clothes. To be patient-centred, we have to acknowledge what it is like to be a patient. I believe the most compelling way to gain this perspective is through storytelling.
Storytelling involves the lesser-known EBM: emotion-based medicine. A patient's description of an encounter with the health care system can be more impactful than a landmark clinical trial, because it forces us to share the patient's emotional experience. What may be routine for us, as health care providers, is often frightening and incomprehensible to patients and/or their families. Storytelling is about the human experience, and telling one's own story is not an easy thing to do-it can conjure feelings of vulnerability, insecurity, and self-doubt. However, we must embrace a culture that empowers patients to share their stories. The 2016 CSHP position statements on pharmacy practice in hospitals and other collaborative health care settings state that the provision of patient-centred care should involve "listening to, understanding, and respecting the patient's story about experiences and expectations that will affect the use of medications." 2 Health care is complex, and patients routinely feel anxious and insignificant when faced with the impatience, apathy, and condescension that occasionally contaminate our overburdened system. Thus, we sometimes need to be reminded that caring is a fundamental aspect of being a health care professional, and that patients commonly perceive the quality of their care not in terms of technical minutiae, which they may or may not be qualified to judge, but in terms of the ability of the health care team to meet their needs in a respectful manner. To quote Jeff Whissell, a pharmacist colleague from Edmonton, "Patients won't remember the dosage change you make, but they are going to remember how you made them feel." I was struck by the power of storytelling as a means to promote patient-centredness at a CSHP Alberta Branch continuing education event in 2014. Sue Robins, a writer and speaker specializing in patient and family engagement, shared her personal experiences with the health care system. Sue's aims are to motivate, inspire, and educate for positive change in health care, and she advocates that patients do better when they themselves feel cared for.
We are taught empathy in our pharmacy training, but I do not think one can really appreciate the patient experience without having personally accessed the health care system. When my son was born, my wife had a potentially life-threatening complication, which was by far the most terrifying incident of our lives. In the 3 years since, my son, like most children, has been to the emergency department at our local hospital multiple timesfor fifth disease, croup, and otitis media (to name a few of his diagnoses)-and each time my persona as the objective, rational health care professional has been replaced by that of the anxious, irrational father. I am lucky, in that both my wife and our son are healthy, but through these interactions I have realized first-hand that most negative interactions between patients/families and health care providers are derived from fear and stress. When I access the health care system, I am unapologetically abrasive toward the "business-as-usual" approach, but soften to deference and appreciation with the smallest demonstration of care. These experiences have precipitated new-found respect for my patients. I now make more of an effort to demonstrate empathy in simple and practical ways with the goal of, if nothing else, reassuring the patient that we (i.e., the health care team) are there to take care of them and support their active participation in decision-making.
Despite our technologies, advanced skills, and scientific evidence, health care, at its core, is about providing care, which is rooted in emotion. And there is no better way to evoke emotion than a good story. When you provide care to your patients, I encourage you to avoid focusing just on their problems-instead, focus on each patient's story.
Implications of Changes to the Mefloquine Product Monograph
In August 2016, Health Canada approved significant changes to the Canadian product monograph for mefloquine, a drug licensed in Canada since 1993 for the prevention and treatment of malaria. These changes mirror those made in the United States and Europe, including the addition of a "serious warnings and precautions" box (or "boxed warning"), which includes warnings that differ substantively in 2 key ways from prior language. 1 First, the previous product monograph warned only that "If signs of acute anxiety, depression, restlessness or confusion occur during prophylactic use, these may be considered prodromal to a more serious event. In these cases, the drug must be discontinued and an alternative medication should be substituted".
2 Although this warning remains, the new monograph also warns that mefloquine "should" be discontinued "if psychiatric or neurologic symptoms occur". 1 Second, the previous product monograph warned only that "Adverse reactions to [mefloquine] may occur or persist up to several weeks after discontinuation of the drug. In a small number of patients it has been reported that dizziness or vertigo and loss of balance may continue for months after discontinuation".
2 In contrast, the new monograph warns that "Psychiatric symptoms . . . on occasions . . . have been reported to continue long after mefloquine has been stopped" and "In a small number of patients it has been reported that dizziness or vertigo and loss of balance may continue for months or years after discontinuation of mefloquine, and in some cases vestibular damage may be permanent". 1 These changes follow similar changes first made in the United States in 2013. At that time, Health Canada officials determined that no corresponding changes were needed to the Canadian product monograph. 3 However, in 2014, regulators at the European Medicines Agency (EMA) recommended that substantially similar warnings be added throughout the European medicines regulatory network. 4 The EMA concluded that there was sufficient evidence "supporting a causal relationship between mefloquine and the occurrence of long lasting and even persistent neuropsychiatric effects" and speculated that these were due to "permanent brain damage". The EMA review noted that no risk factors could be identified for this effect, and that for this reason "only the advice-to stop taking mefloquine if neuropsychiatric reactions or changes to their mental state occur-can be given as a precautionary measure". 4 Warnings in the United Kingdom and Ireland were subsequently strengthened, emphasizing that even abnormal dreams or nightmares should prompt the drug's discontinuation. 5 In May 2016, a comparison of international drug safety documentation was published, 5 which noted significant discrepancies between warnings in the United States, Ireland, and the United Kingdom and warnings in the then-current Canadian product monograph. The subsequently updated Canadian product monograph brought Canadian warnings closer to the international consensus. A Health Canada official would later state that these changes were requested in response to its guidelines for "plain language labelling" published in 2014. 3 The new warnings have important implications for Canadian pharmacists counselling their patients on the use of mefloquine. In particular, in accordance with warnings in the United Kingdom and Ireland, abnormal dreams or nightmares may now need to be considered among the neurologic and psychiatric symptoms for which discontinuation of mefloquine is recommended. 5 In contrast, early recommendations for the use of mefloquine by the Canadian Committee to Advise on Tropical Medicine and Travel (CATMAT) described strange dreams and nightmares as "minor side effects", 6 and the previous Canadian product monograph had stated that "difficulty sleeping, and bad dreams are usually mild and do not cause people to stop taking the medicine".
2 Today, Roche-which withdrew its branded version of mefloquine (Lariam) from the Canadian market in 2013 but continues to market this product in other countries
